Breaking
new ground

in immuno-oncology

Breaking
new ground

in immuno-oncology

Immunocore

Immunocore is a world-leading biotechnology company focused on the development of a new class of immunotherapeutic drugs, based on proprietary T cell receptor (TCR) technology. The Company is focusing its technology primarily in the area of immuno-oncology via the ImmTAC platform. The same underlying technology is being extended to address other hard to treat conditions including viral infections, through the ImmTAV platform, and autoimmune diseases. The scientific expertise at Immunocore spans the entire process of drug development. From the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, to preclinical and clinical assessment.

panel-1.jpg

Discovery and
validation of novel
disease targets
 

Learn more

 

panel-2.jpg

ImmTACs – redefining
immuno-oncology
through TCR targeted
T cell redirection

Learn more

 

panel-3.jpg

ImmTACs in the
clinic – delivering
better tomorrows
 

Learn more